(redirected from Brintellix)




(trade name)


Therapeutic: antidepressants
Pharmacologic: selective serotonin reuptake inhibitors ssris
Pregnancy Category: C


Treatment of major depressive disorder.


Selectively inhibits the reuptake of serotonin in the CNS.

Therapeutic effects

Antidepressant action.


Absorption: Well absorbed (75%) following oral administration.
Distribution: Extensive extravascular distribution
Protein Binding: 98%.
Metabolism and Excretion: Extensively metabolized, primarily by the CYP2D6 enzyme system, 59% excreted in urine as metabolites, 26% in feces as metabolites, minimal renal excretion of unchanged drug.
Half-life: 66 hr.

Time/action profile (antidepressant effect)

PO1–2 wk4–8 wkunknown


Contraindicated in: Hypersensitivity;Concurrent or recent MAOIs for psychiatric use, linezolid or IV methylene blue; Obstetric: May cause fetal harm (third trimester use may result in respiratory distress, cyanosis, apnea, seizures, temperature instability feeding difficulties and behavioral issues infants, may also be associated with persistent pulmonary hypertension of the newborn [PPHN]); Lactation: Discontinue drug or discontinue breast feeding.
Use Cautiously in: History of bipolar disorder (may activate mania/hypomania);History of suicide attempt/ideation; genetic implication Poor CYP2D6 metabolizers will have ↑ blood levels; Geriatric: ↑ risk of hyponatremia; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects


  • constipation (most frequent)
  • nausea (most frequent)

Fluid and Electrolyte

  • hyponatremia


  • sexual dysfunction (most frequent)


  • bleeding


  • allergic reactions including angioedema
  • serotOnin syndrome (life-threatening)


Drug-Drug interaction

Concurrent use of MAOIs for psychiatric conditions or within 21 days of discontinuing vorioxetine is contraindicated; do not use vorioxetine within 14 days of discontinuing MAOIs used for psychiatric conditions, nor should vorioxetine be started in patients receiving linezolid or intravenous methylene blue due to risk of serious adverse reactions including serotonin syndrome.↑ risk of serotonin syndrome with other SSRIs, SNRIs, buspirone, fentanyl, lithium, tramadol, tricyclic antidepressants, triptans and tryptophan.Strong inhibitors of CYP2D6bupropion, fluoxetine, paroxetine, or quinidine ↑ blood levels and effects (decrease dose by 50%).Strong inducers of CYP2D6carbamazepine, phenytoin, rifampin ↓ blood levels and effectiveness, consider larger doses of vorioxetine if used for longer than 14 days (not to exceed three times original dose).↑ risk of bleeding with aspirin, NSAIDs, anticoagulants, thrombolytics, antiplatelet agents and other drugs affecting coagulation.↑ risk of serotonin syndrome with St. John's wort.


Oral (Adults) 10 mg once daily initially, may be increased to 20 mg once daily; some patients may only tolerate daily doses of 5 mg; CYP2D6 poor metabolizers—daily dose should not exceed 10 mg; concurrent use of inhibitors of CYP2D6—reduce dose by 50%; concurrent use of strong inducers of CYP2D6 for more than 14 days—consider increased dose (not to exceed three times original dose). If daily dose 15–20 mg/day, do not discontinue abruptly; taper to 10 mg/day for one week before discontinuing.


Immediate-release tablets: 5 mg, 10 mg, 15 mg, 20 mg

Nursing implications

Nursing assessment

  • Monitor mood changes. Inform health care professional if patient demonstrates significant increase in anxiety, nervousness, or insomnia.
  • Assess for suicidal tendencies, especially during early therapy. Restrict amount of drug available to patient. Risk may be increased in children, adolescents, and adults ≤24 yr. After starting therapy, children, adolescents, and young adults should be seen by health care professional at least weekly for 4 wk, every 3 wk for next 4 wk, and on advice of health care professional thereafter.
  • Monitor for signs and symptoms of hypersensitivity reactions (rash, hives, swelling, difficulty breathing). Stop vortioxetine and treat symptomatically.
  • Assess for sexual side effects (erectile dysfunction; decreased libido).
  • Monitor for serotonin syndrome (mental changes [agitation, hallucinations, coma], autonomic instability [tachycardia, labile BP, hyperthermia], neuromuscular aberrations [hyperreflexia, incoordination], and/or GI symptoms [nausea, vomiting, diarrhea]), especially in patients taking other serotonergic drugs (SSRIs, SNRIs, triptans).
  • Lab Test Considerations: May cause hyponatremia.

Potential Nursing Diagnoses

Ineffective coping (Indications)
Risk for injury (Side Effects)
Sexual dysfunction (Side Effects)


  • To avoid serotonin syndrome, allow at least 14 days between discontinuation of an MAO inhibitor and starting vortioxetine. Allow at least 21 days after stopping vortioxetine before starting an MAO inhibitor.
  • Oral: Administer once daily at the same time each day without regard to meals.

Patient/Family Teaching

  • Instruct patient to take vortioxetine at the same time each day as directed. Advise patient taking 15 mg/day or 20 mg/day of vortioxetine not to stop abruptly; may cause headache, muscle tension, mood swings, sudden outburst of anger, dizziness, and runny nose. Instruct patient to read Medication Guide before starting therapy and with each Rx refill in case of changes.
  • Inform patient that nausea is common in first wk of therapy and is dose related. Usually decreases in frequency after first wk, but may persist.
  • Caution patient to report signs and symptoms of hyponatremia (headache, difficulty concentrating, memory impairment, confusion, weakness, unsteadiness, and may worsen to hallucinations, syncope, seizures, coma, respiratory arrest, death) to health care professional promptly.
  • Advise patient, family and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care professional immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior or if symptoms of serotonin syndrome occur.
  • Caution patient and caregiver to look for signs of activation of mania/hypomania (greatly increased energy, severe sleeping problems, racing thoughts, reckless behavior, unusually grand ideas, excessive happiness or irritability, talking more or faster than usual), especially in patients with a history or family history of bipolar disorder, mania, or hypomania.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications. Advise patient to avoid taking other CNS depressants or alcohol. Also taking aspirin, NSAIDs, warfarin, or other anticoagulants may increase risk of bleeding.
  • Inform patient that medication may cause decreased libido.
  • Advise patient to notify health care professional if symptoms of hypersensitivity reaction or serotonin syndrome occur or if nausea persists.
  • Instruct female patients to inform health care professional if pregnancy is planned or suspected, or if breastfeeding.
  • Emphasize the importance of follow-up exams to monitor progress.

Evaluation/Desired Outcomes

  • Increased sense of well-being.
    • Renewed interest in surroundings. May require 1–4 wk of therapy to obtain antidepressant effects.
References in periodicals archive ?
M2 PHARMA-December 4, 2017-Lundbeck's Brintellix approved in China
M2 EQUITYBITES-December 4, 2017-Lundbeck's Brintellix approved in China
The nine drugs listed are Entresto ( for heart conditions), Erivedge ( for basal cell carcinoma), Brintellix ( for depression), Otezla ( for psoriasis & psoriatic arthritis), Lynparza ( for ovarian cancer), Gazyvaro (for follicular lymphoma), Entyvio (for Crohn's & ulcerative colitis), Opdivo ( for renal cell carcinoma), Opdivo ( for Hodgkin's lymphoma).
TO AVOID CONFUSION with another drug, the Food and Drug Administration has approved a name change request for the antidepressant Brintellix (vortioxetine), according to a press release from the federal government agency.
The formulation, indication and dosages of Trintellix remain the same as that of Brintellix.
The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Individuals and healthcare professionals who have questions about Brintellix, Trintellix and/or the name change, should contact Takeda at 1-877-TAKEDA-7.
M2 PHARMA-December 31, 2013-H Lundbeck receives marketing authorisation for Brintellix from European Commission
M2 EQUITYBITES-December 31, 2013-H Lundbeck receives marketing authorisation for Brintellix from European Commission
label of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with major depressive disorder (MDD).
It will be marketed as Brintellix, by Takeda Pharmaceuticals and Lundbeck, and will be available in 5-mg, 10-mg, 15-mg, and 20-mg tablets.
Dosage forms Extended-release capsules in 20 mg, 40 mg, 80 mg, and 120 mg strengths Recommended 40 mg to 120 mg capsule once daily with or dosage without food Table 3 Fast facts: Vortioxetine Brand name Brintellix Class Serotonin modulator and stimulator (serotonin reuptake inhibitor; 5-HT1A receptor agonist; 5-HT1B receptor partial agonist; 5-HT3, 5-HT1D, and 5-HT7 receptor antagonist) FDA approval September 30, 2013 date Manufacturer Takeda Pharmaceutical Company Limited & H.